Skip to main content

Table 4 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) and non-inflammatory diseases of the CNS (N-INF) after data reduction with PCA

From: Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

  Disease Predicted Group Membershipb.c Total
RRMS N-INF
Original
 Count RRMS 66 3 69
N-INF 13 29 42
 % RRMS 95.7 4.3 100
N-INF 31.0 69.0 100
Cross-validateda
 Count RRMS 66 3 69
N-INF 13 29 42
 % RRMS 95.7 4.3 100
N-INF 31.0 69.0 100
  1. aCross-validation is done only for those sets of samples analyzed. In cross-validation, each sample is classified by the functions derived from all samples other the one under analysis
  2. b85.6% of original grouped samples correctly classified
  3. c85.6% of cross-validated grouped samples correctly classified